Literature DB >> 22301727

[Hereditary cardiac amyloidosis with transthyretin mutations. A cause of sudden death ].

C Edler1, W Saeger, U Orth, C Braun, B Wulff, J Sperhake.   

Abstract

Hereditary amyloidoses present a clinically and genetically heterogeneous group of autosomal dominant diseases. The most frequent form is associated with mutations of the transthyretin gene. The type of mutation determines the process, the organs primarily involved as well as the time of onset of the disease. Life expectancy is generally limited by the degree of cardiomyopathy. The cases of two male patients who died suddenly and unexpectedly are presented. In both cases, autopsy revealed a biventricular cardiac hypertrophy. Cardiac amyloidosis was diagnosed by means of histologic and genetic analysis. Early diagnosis is essential for those affected, since liver transplantation still represents the only effective treatment. This illustrates the benefit of autopsy investigations for surviving relatives, who may themselves be affected by the disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22301727     DOI: 10.1007/s00059-011-3566-9

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  18 in total

1.  A new isoleucine substitution of Val-20 in transthyretin tetramers selectively impairs dimer-dimer contacts and causes systemic amyloidosis.

Authors:  D E Jenne; K Denzel; P Blätzinger; P Winter; B Obermaier; R P Linke; K Altland
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  Hereditary amyloidosis and cardiomyopathy.

Authors:  M D Benson
Journal:  Am J Med       Date:  1992-07       Impact factor: 4.965

Review 3.  A molecular correlate of clinicopathology in transthyretin amyloidosis.

Authors:  Mark B Pepys
Journal:  J Pathol       Date:  2009-01       Impact factor: 7.996

Review 4.  [Update on immunohistological classification of amyloidoses].

Authors:  C Röcken
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

5.  Transthyretin Val 107 in a Japanese patient with familial amyloid polyneuropathy.

Authors:  Kazunori Nanri; Hiroya Utsumi; Masahito Yamada; Yoshifumi Takata; Atsushi Matsumura; Kazusa Kougo; Shigeo Sekine; Daisaku Ogawa; Mitsuyasu Toyoda
Journal:  J Neurol Sci       Date:  2002-06-15       Impact factor: 3.181

6.  Amyloid polyneuropathy in two German-American families: a new transthyretin variant (Val 107).

Authors:  T Uemichi; M A Gertz; M D Benson
Journal:  J Med Genet       Date:  1994-05       Impact factor: 6.318

7.  Transthyretin VAL107, a new variant associated with familial cardiac and neuropathic amyloidosis.

Authors:  D R Jacobson; M A Gertz; J N Buxbaum
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

Review 8.  [Hereditary amyloidoses associated with transthyretin mutations].

Authors:  E Hund; R Singer; R P Linke; F Willig; A Grau
Journal:  Nervenarzt       Date:  2002-10       Impact factor: 1.214

Review 9.  Amyloidosis and the heart: a comprehensive review.

Authors:  Keyur B Shah; Yoshio Inoue; Mandeep R Mehra
Journal:  Arch Intern Med       Date:  2006-09-25

10.  Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy.

Authors:  V Planté-Bordeneuve; T Lalu; M Misrahi; M M Reilly; D Adams; C Lacroix; G Said
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.